Startup Farsight Aiming for FDA Clearance of its Genomic Analysis Platform

Mar 27, 2018

|

Premium

CHICAGO (GenomeWeb) – Genomic analytics startup Farsight Genome Systems has high ambitions, seeking to gain US Food and Drug Administration clearance of its software for use in labs conducting sequencing-based tests.

"We would like to be the first analytic pipeline that has won FDA clearance," CEO and Founder Glenda Anderson said.

Sunnyvale, California-based Farsight, founded in 2015, has submitted a first demonstration of its Farsight Correo platform to the FDA, according to Anderson, as it seeks 510(k) clearance for the technology.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

Oct

24

Featured Webinar

Designing, Decoding & Delivering on Genetic Testing for Inherited Disease at Versiti

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.

Dec

05

Featured Webinar

Improving the Diagnosis of Infectious Diseases with Microbial Genomic Analysis

The discovery of microbial cell-free DNA has propelled the introduction of new technologies that can be leveraged for next-generation diagnostic assays. Previously inaccessible genomic information can now be comprehensively surveyed for microorganisms, all from a single blood draw.

Dec

10

Featured Webinar

Maximizing Diagnostic Yield with an Optimized Variant Interpretation Platform

This webinar will discuss the use of next-generation sequencing and an optimized variant interpretation workflow to increase diagnostic yield in complex clinical cases.

Menu